Cytosorbents Corp (CTS) 8-K Summary
Business Context and Reporting Period
Cytosorbents Corporation, a Delaware corporation listed on the Nasdaq Capital Market under the symbol CTSO, filed this Form 8-K on March 8, 2022. The filing serves to announce the Company's financial results for the quarter and the twelve months ended December 31, 2021, and to provide an outlook for 2022.
Key Financial Metrics
The filing text does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These details are contained within the press release furnished as Exhibit 99.1, which is referenced but not included in the provided text.
Material Changes
The filing does not explicitly detail material changes versus prior periods within the body text. It directs readers to the attached press release for the comparative financial results.
Guidance and Outlook
Management provided a 2022 outlook in the press release dated March 8, 2022. The filing text does not contain specific guidance figures, risk factors, or management commentary beyond the reference to the external document.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release) for specific Q4 and full-year 2021 revenue and net loss figures.
- Verify the 2022 financial guidance and operational milestones outlined in the press release.
- Confirm cash position and burn rate details not present in the 8-K summary text.
- Check for any updates on regulatory approvals or product commercialization mentioned in the full press release.